Get Started

TRVI

NASD Trevi Therapeutics, Inc.
Nov 5, 2026 · 12:56 PM ET DELAYED Market Open

$13.14 ↓ -0.85 (-6.08%) Trading Down from the previous close of $13.99, $0.87 below the day’s high of $14.01

YTD change
+4.91%
vs 20-day SMA
+1.60%
vs 200-day SMA
-8.74%

Price ranges

Previous day
$13.48 $14.53
open $14.35 close $13.99
-$0.37 (-2.54%)
Today
$13.11 $14.01
open $14.01 now $13.14
-$0.87 (-6.24%)
Past week
$13.21 $14.53
from $13.52 now $13.14
-$0.38 (-2.85%)
Past month
$11.70 $14.53
from $13.14 now $13.14
-$0.00 (-0.04%)
This year
$9.82 $20.22
from $12.52 now $13.14
+$0.62 (+4.91%)

Price & Performance

-0.68 (-4.60%) / 6M

$11.27$14.22$17.16$20.11May 5Aug 5Nov 4

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 35.0% away from all-time highs of $20.22
  • TRVI is up 5% since the beginning of the year
  • TRVI is up 23% over the past 12 months
  • TRVI is down 0% over the past 1 month
  • 13% of all TRVI investors are betting against TRVI

TRVI reads not so good: price sits above one of the two key moving averages, the 12-month move is +31.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.11
Earnings momentum +16.5% Quarterly EPS growth
Quarterly change +16.5%

Valuation

P/E ratio N/A
Enterprise value $1.9B
Beta -0.51

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$318.9M
Debt$605.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $1.9B

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $478.48 +3.73%
MRNA Moderna, Inc. $258.38 +13.11%
RVMD Revolution Medicines, Inc. $199.70 +2.82%
ROIV Roivant Sciences Ltd. $38.23 +6.08%
BNTX BioNTech SE Sponsored ADR $90.70 +4.35%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.